{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:19Z","timestamp":1790936299522,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Brandon's Eye Research Foundation"},{"name":"Perioperative Services Summer Studentship Program at the Hospital for Sick Children, Toronto, Ontario, Canada"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.exer.2018.01.020","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T12:59:43Z","timestamp":1517662783000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The effect of a single anti-Vascular Endothelial Growth Factor injection on neonatal growth and organ development: In-vivo study"],"prefix":"10.1016","volume":"169","author":[{"given":"Sina","family":"Khalili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Shifrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques","family":"Belik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamiar","family":"Mireskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.01.020_bib1","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2018.01.020_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.01.020_bib3","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2016.06.054","article-title":"Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system","volume":"123","author":"Blair","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.01.020_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jss.2006.07.027","article-title":"VEGF is important for early liver regeneration after partial hepatectomy","volume":"138","author":"Bockhorn","year":"2007","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.exer.2018.01.020_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/15569527.2013.855227","article-title":"Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study","volume":"33","author":"Dinc","year":"2014","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.exer.2018.01.020_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2018.01.020_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/hrt.14.3.413","article-title":"Ventricular weight in cardiac hypertrophy","volume":"14","author":"Fulton","year":"1952","journal-title":"Br. Heart J."},{"key":"10.1016\/j.exer.2018.01.020_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"Gerber","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.exer.2018.01.020_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.exer.2018.01.020_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2018.01.020_bib11","article-title":"Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2018.01.020_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1167\/iovs.15-18239","article-title":"Species cross-reactivity of antibodies used to treat ophthalmic conditions","volume":"57","author":"Irani","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.020_bib13","doi-asserted-by":"crossref","first-page":"L600","DOI":"10.1152\/ajplung.2000.279.3.L600","article-title":"Inhibition of angiogenesis decreases alveolarization in the developing rat lung. American journal of physiology","volume":"279","author":"Jakkula","year":"2000","journal-title":"Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.exer.2018.01.020_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.020_bib15","doi-asserted-by":"crossref","first-page":"L555","DOI":"10.1152\/ajplung.00408.2001","article-title":"Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. American journal of physiology","volume":"283","author":"Le Cras","year":"2002","journal-title":"Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.exer.2018.01.020_bib16","doi-asserted-by":"crossref","first-page":"L134","DOI":"10.1152\/ajplung.00050.2004","article-title":"VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. American journal of physiology","volume":"287","author":"Le Cras","year":"2004","journal-title":"Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.exer.2018.01.020_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2018.01.020_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00417-008-0936-y","article-title":"Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?","volume":"247","author":"Lu","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.020_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jb\/mvu031","article-title":"Roles of VEGF-A signalling in development, regeneration, and tumours","volume":"156","author":"Matsumoto","year":"2014","journal-title":"J. Biochem."},{"key":"10.1016\/j.exer.2018.01.020_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1167\/iovs.13-11625","article-title":"Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity","volume":"54","author":"McCloskey","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.020_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2018.01.020_bib22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.exer.2018.01.020_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1046\/j.1471-4159.1998.70051781.x","article-title":"CNS drug design based on principles of blood-brain barrier transport","volume":"70","author":"Pardridge","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.exer.2018.01.020_bib24","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/02713683.2012.669003","article-title":"Avastin treatment reduces retinal neovascularization in a mouse model of retinopathy of prematurity","volume":"37","author":"Rabinowitz","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.01.020_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.020_bib26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.020_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","article-title":"Current and future trends in treatment of severe retinopathy of prematurity","volume":"40","author":"Wallace","year":"2013","journal-title":"Clin. Perinatol."},{"key":"10.1016\/j.exer.2018.01.020_bib28","first-page":"167","article-title":"The blood-brain barrier challenge for the treatment of brain cancer, secondary brain metastases, and neurological diseases","volume":"12","author":"Weidle","year":"2015","journal-title":"Canc. Genom. Proteom."},{"key":"10.1016\/j.exer.2018.01.020_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.exer.2018.01.020_bib30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.exer.2018.01.020_bib31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","article-title":"Effects of vascular endothelial growth factor on hemodynamics and cardiac performance","volume":"27","author":"Yang","year":"1996","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.exer.2018.01.020_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.01.020_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"10.1016\/j.exer.2018.01.020_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clp.2013.02.001","article-title":"Retinopathy of prematurity-incidence today","volume":"40","author":"Zin","year":"2013","journal-title":"Clin. Perinatol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517307194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483517307194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T17:59:33Z","timestamp":1660413573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483517307194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"alternative-id":["S0014483517307194"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.01.020","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of a single anti-Vascular Endothelial Growth Factor injection on neonatal growth and organ development: In-vivo study","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}